OABI — OmniAb, Inc.

OmniAb (OABI) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $14.4 million, up from $4.2 million in Q1 2025, primarily due to increased milestone revenue from partner programs.
• Operating Expenses: Decreased slightly to $22.3 million from $23 million, attributed to lower personnel and service costs. A noncash write-off of $2.9 million impacted the figures.
• Net Loss: $7.7 million ($0.06 per share), improved from a net loss of $18.2 million ($0.17 per share) in the prior year. Excluding the write-off, adjusted loss would be $0.04 per share.
• Cash Position: $49.1 million at the end of the quarter.
• Active Partners: 107, consistent with year-end 2025.
• Active Programs: 409, reflecting normal attrition and new program starts.
• Contracted Milestones: Over $3 billion in total contracted milestones with an average royalty rate of 3.4%.

2. Strategic Updates and Business Highlights

• Technological Advancements: Continued development of OmniUltra and OmnidAb technologies, with a focus on unique antibody repertoires and high-throughput screening capabilities.
• xPloration Platform: Strong interest in this new high-throughput screening platform, expected to generate multiple revenue streams.
• Clinical Pipeline: 32 active clinical programs, with two OmnidAb-derived programs progressing to human trials, including one in Phase II.
• New Partnerships: Recent agreement with Florida State University, highlighting growth in academic collaborations.

3. Forward Guidance and Outlook

• Revenue Guidance for 2026: Revised upward to $28 million to $33 million, reflecting strong Q1 performance and additional milestones achieved.
• Operating Expenses Guidance: Expected to be between $83 million and $88 million, impacted by the noncash impairment charge. Cash operating expenses remain projected at $50 million to $55 million.
• Year-End Cash Projection: Anticipated to end 2026 with $33 million to $38 million in cash and equivalents.

4. Bad News, Challenges, or Points of Concern

• Attrition of Partners: While the number of active partners remained stable, there was noted attrition, which is a normal aspect of the business.
• Market Conditions: Some partners in the industry are facing headwinds, which could impact new program starts and overall demand.
• Dependency on Milestone Revenue: Revenue is still largely milestone-driven, which can be variable and unpredictable.

5. Notable Q&A Insights

• Milestones and ASCO Data: Milestones are generally linked to clinical and regulatory events, but not specifically tied to data disclosures. Upcoming ASCO presentations are expected to enhance visibility for partner assets.
• Impact of AI: The increasing adoption of AI in the industry is viewed as a positive trend that could enhance demand for OmniAb's platforms.
• Immunovant's Batoclimab Update: The failure of Batoclimab in Phase III trials is not expected to impact long-term royalty projections for OmniAb, as Immunovant remains focused on advancing IMVT-1402.
• New Partner Interest: There is a growing interest from tech-focused partners, indicating a potential shift in the mix of partnerships towards data-driven approaches.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A, providing a balanced view of OmniAb's current position and outlook.